Literature DB >> 27016070

The role of growth factors as a therapeutic approach to demyelinating disease.

Yangyang Huang1, Cheryl F Dreyfus2.   

Abstract

A variety of growth factors are being explored as therapeutic agents relevant to the axonal and oligodendroglial deficits that occur as a result of demyelinating lesions such as are evident in Multiple Sclerosis (MS). This review focuses on five such proteins that are present in the lesion site and impact oligodendrocyte regeneration. It then presents approaches that are being exploited to manipulate the lesion environment affiliated with multiple neurodegenerative diseases and suggests that the utility of these approaches can extend to demyelination. Challenges are to further understand the roles of specific growth factors on a cellular and tissue level. Emerging technologies can then be employed to optimize the use of growth factors to ameliorate the deficits associated with demyelinating degenerative diseases.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BDNF; CNTF; Cuprizone; Demyelinating disease; EAE; FGF; IGF-I; Lysolecithin; MS; PDGF; Therapeutic approaches to degenerative disease

Mesh:

Substances:

Year:  2016        PMID: 27016070      PMCID: PMC5010931          DOI: 10.1016/j.expneurol.2016.02.023

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  194 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis.

Authors:  X Liu; D L Yao; H Webster
Journal:  Mult Scler       Date:  1995-04       Impact factor: 6.312

3.  The effects of the growth factor-antagonist, trapidil, on remyelination in the CNS.

Authors:  J S McKay; W F Blakemore; R J Franklin
Journal:  Neuropathol Appl Neurobiol       Date:  1997-02       Impact factor: 8.090

4.  Insulin-like growth factor-I receptors in normal appearing white matter and chronic plaques in multiple sclerosis.

Authors:  N Wilczak; J De Keyser
Journal:  Brain Res       Date:  1997-10-24       Impact factor: 3.252

Review 5.  Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.

Authors:  Li-Jin Chew; Cynthia A DeBoy
Journal:  Neuropharmacology       Date:  2015-06-24       Impact factor: 5.250

6.  Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.

Authors:  Ralf A Linker; De-Hyung Lee; Seray Demir; Stefan Wiese; Niels Kruse; Ines Siglienti; Ellen Gerhardt; Harald Neumann; Michael Sendtner; Fred Lühder; Ralf Gold
Journal:  Brain       Date:  2010-08       Impact factor: 13.501

7.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Authors:  Christine Stadelmann; Martin Kerschensteiner; Thomas Misgeld; Wolfgang Brück; Reinhard Hohlfeld; Hans Lassmann
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

8.  Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection.

Authors:  Muge Yemisci; Secil Caban; Yasemin Gursoy-Ozdemir; Sevda Lule; Ramon Novoa-Carballal; Ricardo Riguera; Eduardo Fernandez-Megia; Karine Andrieux; Partick Couvreur; Yilmaz Capan; Turgay Dalkara
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

9.  Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination.

Authors:  Jeffrey L Mason; Shouhong Xuan; Ioannis Dragatsis; Argiris Efstratiadis; James E Goldman
Journal:  J Neurosci       Date:  2003-08-20       Impact factor: 6.167

10.  Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients.

Authors:  Ranjan Dutta; Jennifer McDonough; Ansi Chang; Lakshman Swamy; Alan Siu; Grahame J Kidd; Richard Rudick; Karoly Mirnics; Bruce D Trapp
Journal:  Brain       Date:  2007-10       Impact factor: 13.501

View more
  18 in total

1.  Inhibition of astrocyte FAK-JNK signaling promotes subventricular zone neurogenesis through CNTF.

Authors:  Cuihong Jia; Matthew P Keasey; Chiharu Lovins; Theo Hagg
Journal:  Glia       Date:  2018-11       Impact factor: 7.452

2.  Neuronal activity in vivo enhances functional myelin repair.

Authors:  Fernando C Ortiz; Chloé Habermacher; Mariana Graciarena; Pierre-Yves Houry; Akiko Nishiyama; Brahim Nait Oumesmar; María Cecilia Angulo
Journal:  JCI Insight       Date:  2019-03-21

Review 3.  Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.

Authors:  Giuseppe Scalabrino
Journal:  Biomedicines       Date:  2022-03-30

Review 4.  The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity.

Authors:  Josine E G Vaes; Myrna J V Brandt; Nikki Wanders; Manon J N L Benders; Caroline G M de Theije; Pierre Gressens; Cora H Nijboer
Journal:  Glia       Date:  2020-11-30       Impact factor: 7.452

5.  Impact of neonatal hypoxia-ischaemia on oligodendrocyte survival, maturation and myelinating potential.

Authors:  Malgorzata Ziemka-Nalecz; Justyna Janowska; Lukasz Strojek; Joanna Jaworska; Teresa Zalewska; Malgorzata Frontczak-Baniewicz; Joanna Sypecka
Journal:  J Cell Mol Med       Date:  2017-08-07       Impact factor: 5.310

6.  Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.

Authors:  Violaine K Harris; James Stark; Tamara Vyshkina; Leslie Blackshear; Gloria Joo; Valentina Stefanova; Gabriel Sara; Saud A Sadiq
Journal:  EBioMedicine       Date:  2018-02-03       Impact factor: 8.143

7.  Lipid Nanoparticles Vectorized with NFL-TBS.40-63 Peptide Target Oligodendrocytes and Promote Neurotrophin-3 Effects After Demyelination In Vitro.

Authors:  Catherine Fressinaud; Olivier Thomas; Anita Monika Umerska; Patrick Saulnier
Journal:  Neurochem Res       Date:  2020-09-10       Impact factor: 3.996

8.  Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes.

Authors:  Ranjithkumar Rajendran; Gregor Böttiger; Niklas Dentzien; Vinothkumar Rajendran; Bischand Sharifi; Süleyman Ergün; Christine Stadelmann; Srikanth Karnati; Martin Berghoff
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

9.  Transplantation of induced neural stem cells (iNSCs) into chronically demyelinated corpus callosum ameliorates motor deficits.

Authors:  Genevieve M Sullivan; Andrew K Knutsen; Luca Peruzzotti-Jametti; Alexandru Korotcov; Asamoah Bosomtwi; Bernard J Dardzinski; Joshua D Bernstock; Sandra Rizzi; Frank Edenhofer; Stefano Pluchino; Regina C Armstrong
Journal:  Acta Neuropathol Commun       Date:  2020-06-09       Impact factor: 7.801

10.  Tropomyosin Receptor Kinase B Expressed in Oligodendrocyte Lineage Cells Functions to Promote Myelin Following a Demyelinating Lesion.

Authors:  Yangyang Huang; Yeri J Song; Maria Isaac; Shir Miretzky; Ashish Patel; W Geoffrey McAuliffe; Cheryl F Dreyfus
Journal:  ASN Neuro       Date:  2020 Jan-Dec       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.